

SEQUENCE LISTING

<110> Quirk, Stephen

Tyrrell, David

<120> Design and Use of Advanced Zinc Chelating Peptides to Regulate Matrix Metalloproteinases

<130> 44039-227522 11301-0200

<160> 10

<170> PatentIn version 3.0

<210> 1

<211> 7

<212> PRT

<213> Synthetic Peptide

<220>

<221> VARIANT

<222> (2)..(2)

<223> X = Ser or Thr

<220>

<221> VARIANT

<222> (4)..(4)

<223> X = Ser, Ala or Val

<400> 1

Cys Xaa Cys Xaa Pro His Pro
 1 5

<210> 2

<211> 12

<212> PRT

<213> Synthetic Peptide

<220>

<221> VARIANT

<222> (1)..(1)

<223> X = Ile or Val

<220>

<221> VARIANT

<222> (2)..(2)

<223> X = Glu, Gln or Arg

<220>

<221> VARIANT

<222> (3)..(3)

<223> X = Phe or Tyr

<220>

<221> VARIANT

<222> (4)..(4)

<223> X = Ile or Val

<220>

<221> VARIANT

<222> (5)..(5)

00753139.123003

$\langle 220 \rangle$ $\langle 222 \rangle \quad (7) \dots (7)$

<220>

<222> (8) . . (8)

 $\langle 220 \rangle$

<222> (9) . . (9)

 $\langle 220 \rangle$ $\langle 222 \rangle \quad (10) \dots (10)$ $\langle 220 \rangle$ $\langle 222 \rangle \quad (11) \dots (11)$ $\langle 220 \rangle$

<221> VARIANT

<222> (12)..(12)

<223> X = Cys or Gly

<400> 2

Xaa Xaa Xaa Xaa Xaa Thr Xaa Xaa Xaa Xaa Xaa Xaa
1 5 10

<210> 3

<211> 9

<212> PRT

<213> Synthetic Oligonucleotide

<220>

<221> VARIANT

<222> (1)..(1)

<223> X = Met, Val or Leu

<220>

<221> VARIANT

<222> (2)..(2)

<223> X = His, Phe or Tyr

<220>

<221> VARIANT

<222> (3)..(3)

<223> X = Ile or Thr

<220>

<221> VARIANT

<222> (4)..(4)

<223> X = Thr, His or Gly

00753139.1.22900

<221> VARIANT

<222> (5) . . (5)

<223> X = Leu or Thr

<220>

<221> VARIANT

 $\langle 222 \rangle \quad (7) \dots (7)$

<223> X = Asp, Asn or Ser

<220>

<221> VARIANT

<222> (8) . . (8)

<223> X = Phe or Tyr

<220>

<221> VARIANT

<222> (9) . . (9)

<223> X = Ile or Val

<400> 3

Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa
1 5

<210> 4

<211> 7

<212> PRT

<213> Synthetic Oligonucleotide

<400> 4

Cys Ser Ala Val Pro Val His
1 5

<210> 5

<211> 7

<212> PRT

<213> Synthetic Peptide

<400> 5

Asp Ser Ala Val Pro Val His
1 5

<210> 6

<211> 9

<212> PRT

<213> Synthetic Peptide

<400> 6

Ile Tyr Thr Ala Cys Met Ser Ala Val
1 5

<210> 7

<211> 7

<212> PRT

<213> Synthetic Peptide

<400> 7

Val His Thr His Leu Cys Asp
1 5

<210> 8

<211> 5

<212> PRT

<213> Synthetic Peptide

<400> 8

Cys Thr Cys Val Pro
1 5

<210> 9

<211> 4

<212> PRT

<213> Synthetic Peptide

<400> 9

Cys Asp Ile Cys
1

<210> 10

<211> 5

<212> PRT

<213> Synthetic Peptide

<400> 10

His Thr Ile Thr His
1 5